Annual EBITDA
-$76.03 M
-$4.99 M-7.02%
31 December 2021
Summary:
Concert Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently -$76.03 million, with the most recent change of -$4.99 million (-7.02%) on 31 December 2021. During the last 3 years, it has fallen by -$4.99 million (-7.02%).CNCE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$29.30 M
-$3.94 M-15.52%
30 September 2022
Summary:
Concert Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently -$29.30 million, with the most recent change of -$3.94 million (-15.52%) on 30 September 2022.CNCE Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$123.00 M
-$2.88 M-2.39%
30 September 2022
Summary:
Concert Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently -$123.00 million, with the most recent change of -$2.88 million (-2.39%) on 30 September 2022.CNCE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CNCE EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -7.0% | -10.9% | -90.7% |
| 5 y5 years | -39.9% | -64.3% | -60.8% |
CNCE EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -178.2% | -122.4% | -215.3% |
Concert Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2022 | - | -$29.30 M(+15.5%) | -$123.00 M(+2.4%) |
| June 2022 | - | -$25.37 M(-29.0%) | -$120.13 M(+36.3%) |
| Mar 2022 | - | -$35.71 M(+9.4%) | -$88.15 M(+15.9%) |
| Dec 2021 | -$76.03 M(+7.0%) | -$32.63 M(+23.5%) | -$76.03 M(+17.9%) |
| Sept 2021 | - | -$26.43 M(-499.7%) | -$64.51 M(+13.1%) |
| June 2021 | - | $6.61 M(-128.0%) | -$57.04 M(-25.3%) |
| Mar 2021 | - | -$23.59 M(+11.8%) | -$76.39 M(+7.5%) |
| Dec 2020 | -$71.04 M(-8.2%) | -$21.11 M(+11.3%) | -$71.04 M(+0.8%) |
| Sept 2020 | - | -$18.96 M(+48.9%) | -$70.48 M(+1.6%) |
| June 2020 | - | -$12.73 M(-30.2%) | -$69.36 M(-8.3%) |
| Mar 2020 | - | -$18.24 M(-11.2%) | -$75.64 M(-2.2%) |
| Dec 2019 | -$77.35 M(+42.4%) | -$20.55 M(+15.2%) | -$77.35 M(+1.1%) |
| Sept 2019 | - | -$17.84 M(-6.2%) | -$76.50 M(+1.1%) |
| June 2019 | - | -$19.02 M(-4.7%) | -$75.64 M(+6.9%) |
| Mar 2019 | - | -$19.95 M(+1.3%) | -$70.73 M(+30.2%) |
| Dec 2018 | -$54.34 M(-155.9%) | -$19.69 M(+16.0%) | -$54.34 M(+26.6%) |
| Sept 2018 | - | -$16.97 M(+20.2%) | -$42.93 M(-140.8%) |
| June 2018 | - | -$14.12 M(+297.2%) | $105.15 M(-1.4%) |
| Mar 2018 | - | -$3.55 M(-57.1%) | $106.69 M(+10.0%) |
| Dec 2017 | $97.16 M | -$8.28 M(-106.3%) | $97.03 M(+3.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2017 | - | $131.11 M(-1142.4%) | $93.50 M(-291.9%) |
| June 2017 | - | -$12.58 M(-4.9%) | -$48.73 M(-1.3%) |
| Mar 2017 | - | -$13.22 M(+12.0%) | -$49.38 M(-1.1%) |
| Dec 2016 | -$49.83 M(-293.9%) | -$11.80 M(+6.1%) | -$49.92 M(+34.2%) |
| Sept 2016 | - | -$11.13 M(-15.8%) | -$37.20 M(+7.8%) |
| June 2016 | - | -$13.22 M(-3.9%) | -$34.52 M(-267.5%) |
| Mar 2016 | - | -$13.76 M(-1604.3%) | $20.60 M(-19.8%) |
| Dec 2015 | $25.70 M(-187.1%) | $915.00 K(-110.8%) | $25.70 M(+59.4%) |
| Sept 2015 | - | -$8.45 M(-120.2%) | $16.12 M(-6.9%) |
| June 2015 | - | $41.90 M(-583.2%) | $17.31 M(-154.1%) |
| Mar 2015 | - | -$8.67 M(+0.1%) | -$31.98 M(+8.4%) |
| Dec 2014 | -$29.50 M(+869.3%) | -$8.66 M(+19.3%) | -$29.50 M(+13.1%) |
| Sept 2014 | - | -$7.26 M(-1.7%) | -$26.07 M(+1.9%) |
| June 2014 | - | -$7.39 M(+19.3%) | -$25.59 M(+202.8%) |
| Mar 2014 | - | -$6.19 M(+18.2%) | -$8.45 M(+177.7%) |
| Dec 2013 | -$3.04 M(-82.2%) | -$5.24 M(-22.8%) | -$3.04 M(-35.2%) |
| Sept 2013 | - | -$6.78 M(-169.5%) | -$4.70 M(-325.4%) |
| June 2013 | - | $9.75 M(-1348.7%) | $2.08 M(-127.2%) |
| Mar 2013 | - | -$781.00 K(-88.7%) | -$7.67 M(+11.3%) |
| Dec 2012 | -$17.14 M(+77.0%) | -$6.89 M | -$6.89 M |
| Dec 2011 | -$9.68 M | - | - |
FAQ
- What is Concert Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Concert Pharmaceuticals?
- What is Concert Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Concert Pharmaceuticals?
- What is Concert Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Concert Pharmaceuticals?
What is Concert Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of CNCE is -$76.03 M
What is the all time high annual EBITDA for Concert Pharmaceuticals?
Concert Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is $97.16 M
What is Concert Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of CNCE is -$29.30 M
What is the all time high quarterly EBITDA for Concert Pharmaceuticals?
Concert Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $131.11 M
What is Concert Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of CNCE is -$123.00 M
What is the all time high TTM EBITDA for Concert Pharmaceuticals?
Concert Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $106.69 M